share_log

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight

Cantor Fitzgerald Reiterates Overweight on Arcturus Therapeuticsto Overweight

Cantor Fitzgerald重申對Arcturus Therapeutics的投資評級爲增持
Benzinga ·  2024/12/16 21:16

Cantor Fitzgerald analyst Pete Stavropoulos reiterates Arcturus Therapeutics (NASDAQ:ARCT) from Overweight to Overweight.

Cantor Fitzgerald 分析師Pete Stavropoulos將Arcturus Therapeutics(納斯達克:ARCT)從增持上調至增持。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論